{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:54:53Z","timestamp":1791338093214,"version":"4.3.1"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.biopha.2016.12.010","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T09:30:59Z","timestamp":1482312659000},"page":"343-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Multiple sclerosis: Therapeutic applications of advancing drug delivery systems"],"prefix":"10.1016","volume":"86","author":[{"given":"Sanam","family":"Dolati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Babaloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Jadidi-Niaragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormoz","family":"Ayromlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Sadreddini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2016.12.010_bib0005","series-title":"McAlpine\u2018s Multiple Sclerosis","article-title":"The story of multiple sclerosis","author":"Compston","year":"1998"},{"key":"10.1016\/j.biopha.2016.12.010_bib0010","first-page":"1","article-title":"Multiple sclerosis in men: management considerations","author":"Bove","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0015","first-page":"1","article-title":"The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis","author":"Safarzadeh","year":"2016","journal-title":"Inflamm. Res."},{"issue":"9963","key":"10.1016\/j.biopha.2016.12.010_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Naghavi","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2016.12.010_bib0025","first-page":"1","article-title":"IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis","author":"Ghalamfarsa","year":"2015","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0030","first-page":"2016","article-title":"Th17Cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications","author":"Passos","year":"2016","journal-title":"Mediators Inflamm."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2012.226","article-title":"Epigenetic changes in patients with multiple sclerosis","volume":"9","author":"Koch","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0040","first-page":"e13","article-title":"The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis","volume":"14","author":"Mirshafiey","year":"2014","journal-title":"Sultan Qaboos University Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/187221311794474900","article-title":"Therapeutic approach to multiple sclerosis by novel oral drugs","volume":"5","author":"Jadidi-Niaragh","year":"2011","journal-title":"Recent Patents Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.biopha.2016.12.010_bib0050","series-title":"Seminars in Hematology","article-title":"Immunological treatment of multiple sclerosis","author":"Diebold","year":"2016"},{"key":"10.1016\/j.biopha.2016.12.010_bib0055","first-page":"1","article-title":"Application of nanomedicine for crossing the blood\u2013brain barrier: theranostic opportunities in multiple sclerosis","author":"Ghalamfarsa","year":"2016","journal-title":"J. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11481-015-9588-y","article-title":"Nanomaterial applications in multiple sclerosis inflamed brain","volume":"10","author":"Ballerini","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"18","key":"10.1016\/j.biopha.2016.12.010_bib0065","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s40265-013-0146-8","article-title":"Promoting remyelination in multiple sclerosis\u2014recent advances","volume":"73","author":"M\u00fcnzel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2016.12.010_bib0070","series-title":"Principles of Deglutition","first-page":"395","article-title":"Progressive neurologic disease and dysphagia (including Parkinson\u2019s disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, post-polio syndrome)","author":"Rosenbek","year":"2013"},{"issue":"May (5)","key":"10.1016\/j.biopha.2016.12.010_bib0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.apjtb.2016.03.009","article-title":"Multiple sclerosis: new insights and trends","volume":"6","author":"Koriem","year":"2016","journal-title":"Asia Pac. J. Trop. Biomed."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","article-title":"Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination","volume":"120","author":"Sharma","year":"2010","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.biopha.2016.12.010_bib0085","first-page":"1","article-title":"Immune-Inflammatory and oxidative and nitrosative stress biomarkers of depression symptoms in subjects with multiple sclerosis: increased peripheral inflammation but less acute neuroinflammation","author":"Kallaur","year":"2015","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/08923971003667627","article-title":"Prostaglandins in pathogenesis and treatment of multiple sclerosis","volume":"32","author":"Mirshafiey","year":"2010","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0095","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/brain\/aws012","article-title":"NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury","volume":"135","author":"Fischer","year":"2012","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.biopha.2016.12.010_bib0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-3083.2012.02769.x","article-title":"The role of natural killer cells in Alzheimer\u2019s disease","volume":"76","author":"Jadidi\u2010Niaragh","year":"2012","journal-title":"Scand. J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/08923973.2010.513391","article-title":"Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis","volume":"33","author":"Jadidi-Niaragh","year":"2011","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.2011.02536.x","article-title":"Th17 cell, the new player of neuroinflammatory process in multiple sclerosis","volume":"74","author":"Jadidi\u2010Niaragh","year":"2011","journal-title":"Scand. J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0115","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s13277-013-0743-x","article-title":"The role of natural killer T cells in B cell malignancies","volume":"34","author":"Ghalamfarsa","year":"2013","journal-title":"Tumor Biol."},{"issue":"248","key":"10.1016\/j.biopha.2016.12.010_bib0120","doi-asserted-by":"crossref","first-page":"248ra106","DOI":"10.1126\/scitranslmed.3008930","article-title":"Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis","volume":"6","author":"Palanichamy","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ana.24088","article-title":"In multiple sclerosis, oligoclonal bands connect to peripheral B\u2010cell responses","volume":"75","author":"Bankoti","year":"2014","journal-title":"Ann. Neurol."},{"issue":"7388","key":"10.1016\/j.biopha.2016.12.010_bib0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature10851","article-title":"Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity","volume":"483","author":"Jiang","year":"2012","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.biopha.2016.12.010_bib0135","doi-asserted-by":"crossref","first-page":"17872","DOI":"10.1073\/pnas.1010201107","article-title":"Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence","volume":"107","author":"Wakim","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0145","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s13277-013-0832-x","article-title":"Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumor Biol."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/08923970903283662","article-title":"Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis","volume":"32","author":"Mirshafiey","year":"2010","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0155","series-title":"The Clinical Neuropsychiatry of Multiple Sclerosis","author":"Feinstein","year":"2007"},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0160","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tins.2009.12.002","article-title":"Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis","volume":"33","author":"Aktas","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2016.12.010_bib0165","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2012.10.055","article-title":"Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview","volume":"60","author":"Mulakayala","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2016.12.010_bib0170","first-page":"948","article-title":"Multiple sclerosis: diagnosis, management and prognosis","volume":"40","author":"Tsang","year":"2011","journal-title":"Aust. Fam. Physician"},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(06)70410-0","article-title":"Secondary progressive multiple sclerosis: current knowledge and future challenges","volume":"5","author":"Rovaris","year":"2006","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuropharm.2010.05.005","article-title":"Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis","volume":"59","author":"Jadidi-Niaragh","year":"2010","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1196\/annals.1394.021","article-title":"Building different mouse models for human MS","volume":"1103","author":"Bettelli","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0190","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaut.2007.12.010","article-title":"Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned?","volume":"30","author":"Burt","year":"2008","journal-title":"J. Autoimmun."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2016.12.010_bib0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12026-015-8719-0","article-title":"Advancing drug delivery systems for the treatment of multiple sclerosis","volume":"63","author":"Tabansky","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.biopha.2016.12.010_bib0200","series-title":"Mayo Clinic Proceedings","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","author":"Wingerchuk","year":"2014"},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2016.12.010_bib0205","first-page":"S17","article-title":"Interferon-\u03b2 mechanisms of action in multiple sclerosis","volume":"74","author":"Dhib-Jalbut","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2016.12.010_bib0210","first-page":"131","article-title":"PEGylated interferon beta-1a in the treatment of multiple sclerosis?an update","volume":"7","author":"Reuss","year":"2013","journal-title":"Biol.: Targets Ther."},{"issue":"5","key":"10.1016\/j.biopha.2016.12.010_bib0215","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/11588120-000000000-00000","article-title":"Glatiramer acetate in the treatment of multiple sclerosis","volume":"25","author":"Lalive","year":"2011","journal-title":"CNS drugs"},{"issue":"5","key":"10.1016\/j.biopha.2016.12.010_bib0220","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/08923973.2011.619987","article-title":"The deviated balance between regulatory T cell and Th17 in autoimmunity","volume":"34","author":"Jadidi-Niaragh","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clinthera.2011.12.006","article-title":"Benefit\u2013Risk analysis of glatiramer acetate for relapsing-Remitting and clinically isolated syndrome multiple sclerosis","volume":"34","author":"Qizilbash","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2016.12.010_bib0230","article-title":"Pharmacogenetic study of long-term response to interferon-\u03b2 treatment in multiple sclerosis","author":"Clarelli","year":"2015","journal-title":"Pharmacogenomics J."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0235","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.autrev.2013.10.012","article-title":"Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature","volume":"13","author":"Mahurkar","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.biopha.2016.12.010_bib0240","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/1352458512438239","article-title":"Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review","volume":"18","author":"Balak","year":"2012","journal-title":"Multiple Scler. J."},{"key":"10.1016\/j.biopha.2016.12.010_bib0245","article-title":"Glatiramer acetate for multiple sclerosis","volume":"5","author":"La Mantia","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2016.12.010_bib0250","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2016.12.010_bib0255","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11910-011-0216-9","article-title":"Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions","volume":"11","author":"Mehling","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.biopha.2016.12.010_bib0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/ecp.12.56","article-title":"Teriflunomide for oral therapy in multiple sclerosis","volume":"5","author":"Papadopoulou","year":"2012","journal-title":"Exp. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0275","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.biopha.2016.03.004","article-title":"Utilization of nanoparticle technology in rheumatoid arthritis treatment","volume":"80","author":"Dolati","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0280","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","article-title":"Immune mechanisms of new therapeutic strategies in MS\u2014Teriflunomide","volume":"142","author":"Claussen","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.expneurol.2014.02.015","article-title":"Mode of action and clinical studies with fumarates in multiple sclerosis","volume":"262","author":"Salmen","year":"2014","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1756285614564152","article-title":"Dimethyl fumarate in the treatment of relapsing\u2013remitting multiple sclerosis: an overview","volume":"8","author":"Bomprezzi","year":"2015","journal-title":"Ther. Adv. Neurol. Disorders"},{"issue":"12","key":"10.1016\/j.biopha.2016.12.010_bib0300","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biopha.2016.12.010_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-013-0394-8","article-title":"Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects","volume":"13","author":"Linker","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.biopha.2016.12.010_bib0310","article-title":"Teriflunomide for multiple sclerosis","volume":"12","author":"He","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2016.12.010_bib0315","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2147\/DDDT.S55308","article-title":"Laquinimod in the treatment of multiple sclerosis: a review of the data so far","volume":"10","author":"Th\u00f6ne","year":"2016","journal-title":"Drug Design, Dev. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2016.12.010_bib0320","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acn3.67","article-title":"Laquinimod reduces neuroaxonal injury through inhibiting microglial activation","volume":"1","author":"Mishra","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0325","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/brain\/awt023","article-title":"Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis","volume":"136","author":"Jolivel","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2016.12.010_bib0330","article-title":"Natalizumab therapy for multiple sclerosis","author":"Derfuss","year":"2013","journal-title":"Seminars in Neurology"},{"key":"10.1016\/j.biopha.2016.12.010_bib0335","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2015-311100","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","author":"McGuigan","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2016.12.010_bib0340","first-page":"S14","article-title":"Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials","volume":"76","author":"Bates","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.biopha.2016.12.010_bib0345","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2165\/11634010-000000000-00000","article-title":"First-Line disease-Modifying therapies in paediatric multiple sclerosis","volume":"72","author":"Johnston","year":"2012","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0350","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/practneurol-2011-000092","article-title":"Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring","volume":"12","author":"Hunt","year":"2012","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0355","article-title":"Rituximab for relapsing-remitting multiple sclerosis","volume":"12","author":"He","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2016.12.010_bib0360","doi-asserted-by":"crossref","DOI":"10.2146\/ajhp140282","article-title":"Role of obinutuzumab in the treatment of chronic lymphocytic leukemia","volume":"72","author":"Jean","year":"2015","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.biopha.2016.12.010_bib0365","series-title":"MAbs","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","author":"Klein","year":"2013"},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0370","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.clinthera.2015.03.001","article-title":"New FDA-approved disease-modifying therapies for multiple sclerosis","volume":"37","author":"English","year":"2015","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2016.12.010_bib0375","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.biopha.2016.12.010_bib0380","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0385","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2006.05.9048","article-title":"Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer","volume":"25","author":"Le Deley","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0390","series-title":"Conn\u2019s Current Therapy 2012","author":"Kellerman","year":"2011"},{"key":"10.1016\/j.biopha.2016.12.010_bib0395","article-title":"Mitoxantrone for multiple sclerosis","volume":"5","author":"Martinelli Boneschi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"September (10)","key":"10.1016\/j.biopha.2016.12.010_bib0400","first-page":"1337","article-title":"Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica","volume":"22","author":"Yamasaki","year":"2015","journal-title":"Multiple Scler. J."},{"key":"10.1016\/j.biopha.2016.12.010_bib0405","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.biopha.2016.08.060","article-title":"Overview on experimental models of interactions between nanoparticles and the immune system","volume":"83","author":"Najafi-Hajivar","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2016.12.010_bib0410","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.biopha.2016.08.020","article-title":"Application of nanoparticle technology in the treatment of Systemic lupus erythematous","volume":"83","author":"Rostamzadeh","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.biopha.2016.12.010_bib0415","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1007\/s13277-015-3706-6","article-title":"Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy","volume":"36","author":"Bahrami","year":"2015","journal-title":"Tumor Biol."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0420","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1900\/RDS.2012.9.305","article-title":"Targeted antigen delivery to DEC-205 (+) dendritic cells for tolerogenic vaccination","volume":"9","author":"Petzold","year":"2012","journal-title":"Rev. Diabet. Stud."},{"issue":"33","key":"10.1016\/j.biopha.2016.12.010_bib0425","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.biomaterials.2008.08.004","article-title":"TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs","volume":"29","author":"Rao","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2016.12.010_bib0430","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","article-title":"Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease","volume":"1200","author":"Wilson","year":"2008","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0435","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann. Neurol."},{"issue":"1525","key":"10.1016\/j.biopha.2016.12.010_bib0440","first-page":"e41","article-title":"Exosome mimetics: a novel class of drug delivery systems","volume":"7","author":"Kooijmans","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2016.12.010_bib0445","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/573528","article-title":"Immunosuppressive exosomes: a new approach for treating arthritis","volume":"2012","author":"Yang","year":"2012","journal-title":"Int. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0450","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10753-012-9539-1","article-title":"Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity","volume":"36","author":"Yin","year":"2013","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0455","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/14737175.2014.890893","article-title":"What are exosomes and how can they be used in multiple sclerosis therapy?","volume":"14","author":"Pusic","year":"2014","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0460","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2013.10.014","article-title":"IFN\u03b3-stimulated dendritic cell exosomes as a potential therapeutic for remyelination","volume":"266","author":"Pusic","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0465","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/glia.22606","article-title":"Youth and environmental enrichment generate serum exosomes containing miR\u2010219 that promote CNS myelination","volume":"62","author":"Pusic","year":"2014","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0470","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.4049\/jimmunol.1500174","article-title":"Peripherally induced tolerance depends on peripheral regulatory T cells that require Hopx to inhibit intrinsic IL-2 expression","volume":"195","author":"Jones","year":"2015","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0475","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1189\/jlb.0711384","article-title":"Dendritic cell-associated lectin 2 (DCAL2) defines a distinct CD8\u03b1- dendritic cell subset","volume":"91","author":"Kasahara","year":"2012","journal-title":"J. Leukoc. Biol."},{"issue":"29","key":"10.1016\/j.biopha.2016.12.010_bib0480","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1016\/j.biomaterials.2012.06.049","article-title":"Microparticle surface modifications targeting dendritic cells for non-activating applications","volume":"33","author":"Lewis","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0485","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/nn405033r","article-title":"A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease","volume":"8","author":"Hunter","year":"2014","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0490","doi-asserted-by":"crossref","first-page":"e87712","DOI":"10.1371\/journal.pone.0087712","article-title":"Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis","volume":"9","author":"White","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0495","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molimm.2013.08.006","article-title":"A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis","volume":"57","author":"Yuan","year":"2014","journal-title":"Mol. Immunol."},{"issue":"28","key":"10.1016\/j.biopha.2016.12.010_bib0500","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1073\/pnas.1120611109","article-title":"Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis","volume":"109","author":"Yeste","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2016.12.010_bib0505","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ni.1915","article-title":"Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells","volume":"11","author":"Gandhi","year":"2010","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0510","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nano.2014.12.003","article-title":"Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction","volume":"11","author":"Gharagozloo","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0515","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrd3916","article-title":"Immunomodulators: particulate promotion of tolerance","volume":"12","author":"Tse","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2016.12.010_bib0520","first-page":"2675","article-title":"Neurobehavioral burden of multiple sclerosis with nanotheranostics","volume":"11","author":"Sriramoju","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0525","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/mp200614q","article-title":"Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis","volume":"9","author":"B\u00fcy\u00fcktimkin","year":"2012","journal-title":"Mol. Pharm."},{"issue":"43","key":"10.1016\/j.biopha.2016.12.010_bib0530","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1016\/j.vaccine.2014.08.016","article-title":"Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis","volume":"32","author":"Cappellano","year":"2014","journal-title":"Vaccine"},{"issue":"219","key":"10.1016\/j.biopha.2016.12.010_bib0535","doi-asserted-by":"crossref","first-page":"219ra7","DOI":"10.1126\/scitranslmed.3007563","article-title":"Therapeutic inflammatory monocyte modulation using immune-modifying microparticles","volume":"6","author":"Getts","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.biopha.2016.12.010_bib0540","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2217\/fon.14.298","article-title":"The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia","volume":"11","author":"Yousefi","year":"2015","journal-title":"Future Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2016.12.010_bib0545","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/gt.2011.159","article-title":"Effect of topical interferon-\u03b3 gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk\/+ mice","volume":"19","author":"Badea","year":"2012","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0550","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0555","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.111.185884","article-title":"Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis","volume":"340","author":"Komano","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2016.12.010_bib0560","series-title":"Seminars in Oncology","article-title":"Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials","author":"Alberts","year":"2004"},{"issue":"12","key":"10.1016\/j.biopha.2016.12.010_bib0565","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.3.12.1739","article-title":"Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy","volume":"3","author":"Batist","year":"2002","journal-title":"Exp. Opin. Pharmacother"},{"issue":"10","key":"10.1016\/j.biopha.2016.12.010_bib0570","doi-asserted-by":"crossref","first-page":"e25721","DOI":"10.1371\/journal.pone.0025721","article-title":"Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids","volume":"6","author":"Avnir","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0575","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jneuroim.2009.05.019","article-title":"Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis","volume":"213","author":"Kizelsztein","year":"2009","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0580","article-title":"Peptide and protein delivery using new drug delivery systems","volume":"30","author":"Jain","year":"2013","journal-title":"Crit. Rev.\u2122 Ther. Drug Carrier Systems"},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0585","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1096\/fj.12-213975","article-title":"Liposome-encapsulated peptides protect against experimental allergic encephalitis","volume":"27","author":"Belogurov","year":"2013","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0590","first-page":"306","article-title":"[Therapeutic effect of encapsulated into the nanocontainers MBP immunodominant peptides on EAE development in DA rats]","volume":"38","author":"Stepanov","year":"2011","journal-title":"Bioorg. Khim."},{"issue":"12","key":"10.1016\/j.biopha.2016.12.010_bib0595","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1021\/nn403743b","article-title":"Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain","volume":"7","author":"Heckman","year":"2013","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.biopha.2016.12.010_bib0600","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.nano.2011.08.013","article-title":"The effects of gold nanoparticles in wound healing with antioxidant epigallocatechin gallate and \u03b1-lipoic acid","volume":"8","author":"Leu","year":"2012","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"issue":"9","key":"10.1016\/j.biopha.2016.12.010_bib0605","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd2805","article-title":"Averting inflammation by targeting the cytokine environment","volume":"9","author":"Kopf","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0610","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1517\/17425247.2014.863872","article-title":"Latent cytokines for targeted therapy of inflammatory disorders","volume":"11","author":"Mullen","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0615","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejpb.2007.01.002","article-title":"Topical non-invasive gene delivery using gemini nanoparticles in interferon-\u03b3-deficient mice","volume":"65","author":"Badea","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2016.12.010_bib0620","article-title":"Recent developments in nanoparticle-based siRNA delivery for cancer therapy","volume":"2013","author":"Lee","year":"2013","journal-title":"BioMed. Res. Int."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0625","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3899\/jrheum.100055","article-title":"Arthritis gene therapy trials reach phase II","volume":"37","author":"Evans","year":"2010","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0630","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.intimp.2010.08.013","article-title":"Curcumin has bright prospects for the treatment of multiple sclerosis","volume":"11","author":"Xie","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0635","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neuropharm.2015.07.013","article-title":"Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair","volume":"99","author":"Mohajeri","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2016.12.010_bib0640","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/824746","article-title":"Encapsulation of curcumin in diblock copolymer micelles for cancer therapy","volume":"2015","author":"Alizadeh","year":"2015","journal-title":"BioMed Res. Int."},{"issue":"7","key":"10.1016\/j.biopha.2016.12.010_bib0645","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/09687688.2010.516276","article-title":"Multifunctionality of lipid-core micelles for drug delivery and tumour targeting","volume":"27","author":"Sawant","year":"2010","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0650","first-page":"451","article-title":"Bioavailability of nanoemulsified conjugated linoleic acid for an antiobesity effect","volume":"8","author":"Kim","year":"2013","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0655","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.bbagen.2012.12.012","article-title":"Incorporation of \u03b2-sitosterol into the membrane increases resistance to oxidative stress and lipid peroxidation via estrogen receptor-mediated PI3 K\/GSK3\u03b2 signaling","volume":"1830","author":"Shi","year":"2013","journal-title":"Biochimica Biophys. Acta (BBA)-Gener. Subjects"},{"issue":"1","key":"10.1016\/j.biopha.2016.12.010_bib0660","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12035-014-9041-x","article-title":"Oxidative stress and neurobiology of demyelination","volume":"53","author":"Ljubisavljevic","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.biopha.2016.12.010_bib0665","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ene.12668","article-title":"Therapeutic interference with leukocyte recirculation in multiple sclerosis","volume":"22","author":"Sellebjerg","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.biopha.2016.12.010_bib0670","first-page":"7165","article-title":"Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant","volume":"10","author":"Binyamin","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.biopha.2016.12.010_bib0675","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1523\/JNEUROSCI.3803-11.2012","article-title":"Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination","volume":"32","author":"Deverman","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2016.12.010_bib0680","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biomaterials.2015.03.044","article-title":"Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)","volume":"56","author":"Rittchen","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2016.12.010_bib0685","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3597","article-title":"iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF","volume":"4","author":"Laterza","year":"2013","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0690","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/glia.22605","article-title":"Astrocyte\u2010specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor","volume":"62","author":"Fischer","year":"2014","journal-title":"Glia"},{"issue":"10","key":"10.1016\/j.biopha.2016.12.010_bib0695","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nn.3505","article-title":"Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells","volume":"16","author":"Kang","year":"2013","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2016.12.010_bib0700","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmed.2011.11.002","article-title":"Targeted nanotherapy for induction of therapeutic immune responses","volume":"18","author":"Metcalfe","year":"2012","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2016.12.010_bib0705","first-page":"1051","article-title":"The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy","volume":"44","author":"Hosseini","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216315700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216315700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:35:32Z","timestamp":1782866132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216315700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":141,"alternative-id":["S0753332216315700"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2016.12.010","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple sclerosis: Therapeutic applications of advancing drug delivery systems","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}